Why GV and Canaan backed Pact Pharma’s hyperpersonalized cancer approach
Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is using an informatics mindset to create hyperpersonalized therapies.
The challenge will be to turn the technology into scalable products that could treat many more patients than other cell-based treatments. ...